Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 3
1970 4
1971 2
1972 1
1973 1
1974 1
1975 4
1976 5
1977 1
1978 2
1980 1
1981 2
1982 3
1984 1
1985 2
1988 3
1989 1
1991 1
1992 1
1993 3
1994 4
1995 4
1996 2
1997 6
1998 2
1999 5
2000 3
2001 3
2002 2
2003 6
2004 4
2005 1
2006 5
2007 5
2008 3
2009 1
2010 3
2011 2
2012 4
2013 7
2014 9
2015 9
2016 5
2017 2
2018 3
2019 5
2020 6
2021 3
2022 3
2023 1
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.
Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E; CRICS-TRIGGERSEP Network. Annane D, et al. N Engl J Med. 2018 Mar 1;378(9):809-818. doi: 10.1056/NEJMoa1705716. N Engl J Med. 2018. PMID: 29490185 Free article. Clinical Trial.
The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortison …
The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Amon …
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.
Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E. Annane D, et al. JAMA. 2002 Aug 21;288(7):862-71. doi: 10.1001/jama.288.7.862. JAMA. 2002. PMID: 12186604 Clinical Trial.
INTERVENTION: Patients were randomly assigned to receive either hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50- micro g tablet once daily) (n = 151) or matching placebos (n = 149) for 7 days. ...CONCLUSION: In our trial, a 7-day treatment wi …
INTERVENTION: Patients were randomly assigned to receive either hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortison …
Fludrocortisone dose-response relationship in septic shock: a randomised phase II trial.
Walsham J, Hammond N, Blumenthal A, Cohen J, Myburgh J, Finfer S, Evans D, Peake S, Kruger P, McCullough J, Johnk L, Ghelani D, Billot L, Shan S, Meyer J, Rajbhandari D, Koch C, Bellomo R, Burrell LM, Young M, Roberts M, Mackenzie L, Medley G, Dalton J, Venkatesh B. Walsham J, et al. Intensive Care Med. 2024 Dec;50(12):2050-2060. doi: 10.1007/s00134-024-07616-z. Epub 2024 Sep 5. Intensive Care Med. 2024. PMID: 39235623 Free PMC article. Clinical Trial.
BACKGROUND: The combination of intravenous hydrocortisone and enteral fludrocortisone may reduce mortality in patients with septic shock. The optimal dose and reliability of absorption of fludrocortisone in critically ill patients are unclear. ...RESULTS: Out of 153 …
BACKGROUND: The combination of intravenous hydrocortisone and enteral fludrocortisone may reduce mortality in patients with septic sh …
Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial.
Heming N, Renault A, Kuperminc E, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Leone M, Timsit JF, Misset B, Benali MA, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Bounab R, Maxime V, Moine P, Bellissant E, Annane D; APROCCHSS investigators; CRICS-TRIGGERSEP network. Heming N, et al. Lancet Respir Med. 2024 May;12(5):366-374. doi: 10.1016/S2213-2600(23)00430-7. Epub 2024 Feb 1. Lancet Respir Med. 2024. PMID: 38310918 Free article. Clinical Trial.
In this subgroup study, patients with CAP were a preselected subgroup for an exploratory secondary analysis of the APROCCHSS trial of hydrocortisone plus fludrocortisone in septic shock. Adults with septic shock were randomised 1:1 to receive, in a double-blind manner, a 7 …
In this subgroup study, patients with CAP were a preselected subgroup for an exploratory secondary analysis of the APROCCHSS trial of hydroc …
Safety and Efficacy of Fludrocortisone in the Treatment of Cerebral Salt Wasting in Patients With Tuberculous Meningitis: A Randomized Clinical Trial.
Misra UK, Kalita J, Kumar M. Misra UK, et al. JAMA Neurol. 2018 Nov 1;75(11):1383-1391. doi: 10.1001/jamaneurol.2018.2178. JAMA Neurol. 2018. PMID: 30105362 Free PMC article. Clinical Trial.
These adverse reactions necessitated discontinuation of fludrocortisone in 2 patients. CONCLUSIONS AND RELEVANCE: Fludrocortisone results in earlier normalization of serum sodium levels, but did not affect outcomes at 6 months. Fludrocortisone had to be withd …
These adverse reactions necessitated discontinuation of fludrocortisone in 2 patients. CONCLUSIONS AND RELEVANCE: Fludrocortisone …
Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH.
Merke DP, Mallappa A, Parker M, Sukin C, Kulkarni SE, Keil MF, Van Ryzin C, Hill SC, Reynolds JC, Cutler GB Jr, Sinaii N. Merke DP, et al. J Clin Endocrinol Metab. 2025 Jun 17;110(7):e2171-e2182. doi: 10.1210/clinem/dgae824. J Clin Endocrinol Metab. 2025. PMID: 39672600 Free PMC article. Clinical Trial.
METHODS: In an open, randomized, controlled trial, children with classic CAH were randomized to receive a combination regimen of antiandrogen, aromatase inhibitor, reduced hydrocortisone, and fludrocortisone prior to puberty or standard therapy (hydrocortisone, fludroco …
METHODS: In an open, randomized, controlled trial, children with classic CAH were randomized to receive a combination regimen of antiandroge …
Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone.
Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF. Freitas J, et al. Clin Auton Res. 2000 Oct;10(5):293-9. doi: 10.1007/BF02281112. Clin Auton Res. 2000. PMID: 11198485 Clinical Trial.
The authors investigated the autonomic and hemodynamic profile of patients with POTS and the effectiveness of bisoprolol and fludrocortisone. The authors evaluated 11 female patients with POTS before and after medical treatment with a cardioselective bisoprolol beta-blocke …
The authors investigated the autonomic and hemodynamic profile of patients with POTS and the effectiveness of bisoprolol and fludrocortis …
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
Aminorroaya A, Tavolinejad H, Sadeghian S, Jalali A, Alaeddini F, Emkanjoo Z, Mollazadeh R, Bozorgi A, Oraii S, Kiarsi M, Shahabi J, Akbarzadeh MA, Rahimi B, Joharimoghadam A, Mohsenizade A, Mohammadi R, Oraii A, Ariannejad H, Apakuppakul S, Ngarmukos T, Tajdini M. Aminorroaya A, et al. Am Heart J. 2021 Jul;237:5-12. doi: 10.1016/j.ahj.2021.03.002. Epub 2021 Mar 6. Am Heart J. 2021. PMID: 33689731 Clinical Trial.
In medication arms, patients will start on 5 mg of midodrine TDS or 0.05 mg of fludrocortisone BD. After one week the dosage will be up-titrated to midodrine 30 mg/day and fludrocortisone 0.2 mg/day. ...CONCLUSION: The COMFORTS trial is the first study that aims to …
In medication arms, patients will start on 5 mg of midodrine TDS or 0.05 mg of fludrocortisone BD. After one week the dosage will be …
Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.
Hamitouche N, Comets E, Ribot M, Alvarez JC, Bellissant E, Laviolle B. Hamitouche N, et al. AAPS J. 2017 May;19(3):727-735. doi: 10.1208/s12248-016-0041-9. Epub 2017 Jan 12. AAPS J. 2017. PMID: 28083797 Clinical Trial.
A one-compartment model was used to describe fludrocortisone and hydrocortisone pharmacokinetics. Mean plasma half-life was 1.40 h (95%CI [0.80;2.10]) for fludrocortisone and 2.10 h (95%CI [1.78;2.40]) for hydrocortisone. ...The administration regimen of fludroco …
A one-compartment model was used to describe fludrocortisone and hydrocortisone pharmacokinetics. Mean plasma half-life was 1.40 h (9 …
Serum aldosterone and cortisol concentrations before and after suppression with fludrocortisone in cats: a pilot study.
Matsuda M, Behrend EN, Kemppainen R, Refsal K, Johnson A, Lee H. Matsuda M, et al. J Vet Diagn Invest. 2015 May;27(3):361-8. doi: 10.1177/1040638715583530. Epub 2015 Apr 21. J Vet Diagn Invest. 2015. PMID: 25901003 Clinical Trial.
Also, cortisol concentrations were measured to assess the potential of fludrocortisone to act as a glucocorticoid in cats. In phase I, 8 healthy laboratory cats were studied in a placebo-controlled, crossover design. ...In both phases, serum aldosterone and cortisol concen …
Also, cortisol concentrations were measured to assess the potential of fludrocortisone to act as a glucocorticoid in cats. In phase I …
154 results